Denniston MM, et al.
Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. Annals of Internal Medicine
2014; 160: 293–300.
Jacobson IM, et al.
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clinical Gastroenterology and Hepatology
2010; 8: 924–933.
Klevens RM, et al.
Evolving epidemiology of hepatitis C virus in the United States. Clinical Infectious Diseases
2012; 55: S3–S9.
Ly KN, et al.
Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases
2016; 62: 1287–1288.
Razavi H, et al.
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology
2013; 57: 2164–2170.
Kinnard EN, et al.
Estimating the true prevalence of hepatitis C in rhode island. Rhode Island Medical Journal
2014; 97: 19–24.
Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Current Opinion in Gastroenterology
2014; 30: 217–222.
Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence
2001; 61: 211–215.
McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver International
2012; 32: 151–156.
Ward JW, Rein DB, Smith BD. Data to guide the ‘test and treat era’ of hepatitis C. Gastroenterology
2012; 143: 887–889.
Kabiri M, et al.
The changing burden of hepatitis C virus infection in the United States: Model-based predictions. Annals of Internal Medicine
2014; 161: 170–180.
Barua S, et al.
Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine
2015; 163: 215–223.
Nguyen JT, et al.
A budget impact analysis of newly available hepatitis C therapeutics and the financial burden on a state correctional system. Journal of Urban Health
2015; 92: 635–649.
Razavi H, et al.
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis
2014; 21: 34–59.
Centers for Disease and Control Prevention (CDC). Hepatitis surveillance. Atlanta, GA: CDC, 2006.
Daniels D, et al.
Surveillance for acute viral hepatitis – United States, 2007. Morbidity and Mortality Weekly Reports. Surveillance Summaries
2009; 58: 1–27.
Wasley A, et al.
Surveillance for acute viral hepatitis – United States, 2005. Morbidity and Mortality Weekly Reports. Surveillance Summaries
2007; 56: 1–24.
Wasley A, et al.
Surveillance for acute viral hepatitis – United States, 2006. Morbidity and Mortality Weekly Reports. Surveillance Summaries
2008; 57: 1–24.
Malling M. Acute and chronic hepatitis C 2009: Statens Serum Institut, 2010. Report No. 19.
Thein HH, et al.
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology
2008; 48: 418–431.
Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in germany: A health technology assessment commissioned by the german federal ministry of health and social security. International Journal of Technology Assessment in Health Care
2005; 21: 55–65.
Sennfält K, et al.
Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in sweden. Scandinavian Journal of Gastroenterology
2001; 36: 870–876.
Freeman AJ, et al.
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology
2001; 34: 809–816.
Fu B, Wang W, Shi X. Impact of delayed diagnosis time in estimating progression rates to hepatitis C virus-related cirrhosis and death. Statistical Methods in Medical Research
2015; 24: 693–710.
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. Journal of Viral Hepatitis
2006; 13: 34–41.
Centers for Disease and Control Prevention. Historical reported cases and estimates. Atlanta, GA: Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2015.
Centers for Disease and Control Prevention (CDC). Viral hepatitis surveillance: United States, 2011. Division of Viral Hepatitis, Atlanta, GA: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2011.
Church D. Hepatitis C surveillance: What does the actual epidemic look like? Commonwealth of Massachusetts Department of Public Health, 2014.
Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC). Viral hepatitis statistics and surveillance. Atlanta, GA: CDC, 2015.
Onofrey S, et al.
Underascertainment of acute hepatitis C virus infections in the U.S. Surveillance system: a case series and chart review. Annals of Internal Medicine
2015; 163: 254–261.
Edlin BR, et al.
Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology
2015; 62: 1353–1363.
Holmberg SD, et al.
Hepatitis C in the United States. New England Journal of Medicine
2013; 368: 1859–1861.
Institute of Medicine (IOM). Hepatitis and Liver Cancer: a National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010.
Davis GL, et al.
Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology
2010; 138: 513–521.
Bruggmann P, et al.
Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis
2014; 21: 5–33.
Volk ML, et al.
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology
2009; 50: 1750–1755.
Kershenobich D, et al.
Applying a system approach to forecast the total hepatitis C virus-infected population size: Model validation using US data. Liver International
2011; 31: 4–17.
Centers for Disease Control and Prevention. Hepatitis C: confirmed antibody, RNA (HCV-RNA), and genotype. National Health and Nutrition Examination Survey, 2015.
Van Nuys K, et al.
Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern. Health Affairs
2015; 34: 1666–1674.
Boccato S, et al.
Fibrosis progression in initially mild chronic hepatitis C. Journal of Viral Hepatitis
2006; 13: 297–302.
Zibbell JE, et al.
Increases in hepatitis C virus infection related to injection drug use among persons aged ⩽30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. Morbidity and Mortality Weekly Report
2015; 64: 453–458.
Anon. SAMSHA, ASAM launch new buprenorphine mentoring program. Alcoholism & Drug Abuse Weekly
2004; 16: 1–3.
Mahajan R, et al.
Mortality among persons in care with hepatitis C virus infection: The chronic hepatitis cohort study (CHeCS), 2006–2010. Clinical Infectious Diseases
2014; 58: 1055–1061.
Sacks-Davis R, et al.
Hepatitis C virus reinfection and spontaneous clearance of reinfection – the inc3 study. Journal of Infectious Diseases
2015; 212: 1407–1419.
Center for Health Law and Policy Innovation of Harvard Law School. Examining hepatitis C treatment access: a review of select state medicaid fee-for-service and managed care program – Rhode Island, 2015.
Müllhaupt B, et al.
Modeling the health and economic burden of hepatitis C virus in switzerland. PLoS ONE
2015; 10: e0125214.
Chahal HS, et al.
Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Internal Medicine
2016; 176: 65–73.